BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9626230)

  • 1. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis.
    Leibman BD; Dillioglugil O; Scardino PT; Abbas F; Rogers E; Wolfinger RD; Kattan MW
    J Clin Oncol; 1998 Jun; 16(6):2267-71. PubMed ID: 9626230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
    Patel A; Dorey F; Franklin J; deKernion JB
    J Urol; 1997 Oct; 158(4):1441-5. PubMed ID: 9302139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.
    Fowler JE; Pandey P; Braswell NT; Seaver L
    Surgery; 1994 Aug; 116(2):302-5; discussion 305-6. PubMed ID: 7519363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of the optimal follow-up schedule after radical prostatectomy.
    Matsumoto K; Niwa N; Hattori S; Takeda T; Morita S; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Asanuma H; Oya M
    Urol Oncol; 2018 Jul; 36(7):341.e9-341.e14. PubMed ID: 29730065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy.
    Goluboff ET; Heitjan DF; DeVries GM; Katz AE; Benson MC; Olsson CA
    J Urol; 1997 Nov; 158(5):1876-8; discussion 1878-9. PubMed ID: 9334621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy].
    Serra AC; Narbón ES
    Arch Esp Urol; 2006 Dec; 59(10):1041-52. PubMed ID: 17283717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation.
    Schaefer U; Witt F; Schueller P; Micke O; Willich N
    Anticancer Res; 2000; 20(6D):4989-92. PubMed ID: 11326654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
    Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
    Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.